Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective

Obesity and dyslipidemia are the main features of metabolic syndrome, expressed mainly by adipose tissue dysfunction and connected by similar pathways and pharmacotherapy. Conventional drugs used in these two associated disorders are limited due to poor drug efficiency, non-specificity, and toxic si...

Descripción completa

Detalles Bibliográficos
Autores principales: Trandafir, Laura M., Dodi, Gianina, Frasinariu, Otilia, Luca, Alina C., Butnariu, Lacramioara I., Tarca, Elena, Moisa, Stefana M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504099/
https://www.ncbi.nlm.nih.gov/pubmed/36145147
http://dx.doi.org/10.3390/nu14183774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504099/
https://www.ncbi.nlm.nih.gov/pubmed/36145147
http://dx.doi.org/10.3390/nu14183774

Ejemplares similares